Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk
Obstructive sleep apnoea (OSA) syndrome is characterised by the presence of apnoea or obstructive hypopnoea during sleep, accompanied by hypoxia. It is estimated that the syndrome affects approximately 10% of men and 15% of women. Diagnosis and treatment rates have increased in recent years, but the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2020-09-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articles/obstructive-sleep-apnoea-syndrome |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256301018316800 |
|---|---|
| author | María Pilar Resano-Barrio Ramón Arroyo-Espliguero María Carmen Viana-Llamas Olga Mediano |
| author_facet | María Pilar Resano-Barrio Ramón Arroyo-Espliguero María Carmen Viana-Llamas Olga Mediano |
| author_sort | María Pilar Resano-Barrio |
| collection | DOAJ |
| description | Obstructive sleep apnoea (OSA) syndrome is characterised by the presence of apnoea or obstructive hypopnoea during sleep, accompanied by hypoxia. It is estimated that the syndrome affects approximately 10% of men and 15% of women. Diagnosis and treatment rates have increased in recent years, but the condition remains undiagnosed in a high percentage of patients. Recent evidence suggests that OSA may increase the risk of cardiovascular disease. The relationship between OSA and cardiovascular disease can be explained, at least in part, by the coexistence of cardiovascular risk factors in the two pathologies, such as age, overweight, smoking and sedentary lifestyle. However, OSA has been independently associated with the risk of developing hypertension, cerebrovascular disease, ischaemic heart disease, heart failure and arrhythmias. Clinical trials that have evaluated the efficacy of continuous positive airway pressure (CPAP) treatment in primary and secondary cardiovascular prevention have not demonstrated a significant reduction in the incidence or recurrence of cardiovascular events. This article analyses the relationship between OSA and cardiovascular risk and discusses recent clinical trials on the efficacy of CPAP in primary and secondary cardiovascular prevention. |
| format | Article |
| id | doaj-art-53d93c7f48fd46cda42e866a214ed627 |
| institution | OA Journals |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-53d93c7f48fd46cda42e866a214ed6272025-08-20T01:56:41ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642020-09-011510.15420/ecr.2020.10Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular RiskMaría Pilar Resano-Barrio0Ramón Arroyo-Espliguero1María Carmen Viana-Llamas2Olga Mediano3Department of Respiratory Medicine, University Hospital, Guadalajara, SpainDepartment of Cardiology, University Hospital, Guadalajara, SpainDepartment of Cardiology, University Hospital, Guadalajara, SpainDepartment of Respiratory Medicine, University Hospital, Guadalajara, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, SpainObstructive sleep apnoea (OSA) syndrome is characterised by the presence of apnoea or obstructive hypopnoea during sleep, accompanied by hypoxia. It is estimated that the syndrome affects approximately 10% of men and 15% of women. Diagnosis and treatment rates have increased in recent years, but the condition remains undiagnosed in a high percentage of patients. Recent evidence suggests that OSA may increase the risk of cardiovascular disease. The relationship between OSA and cardiovascular disease can be explained, at least in part, by the coexistence of cardiovascular risk factors in the two pathologies, such as age, overweight, smoking and sedentary lifestyle. However, OSA has been independently associated with the risk of developing hypertension, cerebrovascular disease, ischaemic heart disease, heart failure and arrhythmias. Clinical trials that have evaluated the efficacy of continuous positive airway pressure (CPAP) treatment in primary and secondary cardiovascular prevention have not demonstrated a significant reduction in the incidence or recurrence of cardiovascular events. This article analyses the relationship between OSA and cardiovascular risk and discusses recent clinical trials on the efficacy of CPAP in primary and secondary cardiovascular prevention.https://www.ecrjournal.com/articles/obstructive-sleep-apnoea-syndrome |
| spellingShingle | María Pilar Resano-Barrio Ramón Arroyo-Espliguero María Carmen Viana-Llamas Olga Mediano Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk European Cardiology Review |
| title | Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk |
| title_full | Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk |
| title_fullStr | Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk |
| title_full_unstemmed | Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk |
| title_short | Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk |
| title_sort | obstructive sleep apnoea syndrome continuous positive airway pressure therapy for prevention of cardiovascular risk |
| url | https://www.ecrjournal.com/articles/obstructive-sleep-apnoea-syndrome |
| work_keys_str_mv | AT mariapilarresanobarrio obstructivesleepapnoeasyndromecontinuouspositiveairwaypressuretherapyforpreventionofcardiovascularrisk AT ramonarroyoespliguero obstructivesleepapnoeasyndromecontinuouspositiveairwaypressuretherapyforpreventionofcardiovascularrisk AT mariacarmenvianallamas obstructivesleepapnoeasyndromecontinuouspositiveairwaypressuretherapyforpreventionofcardiovascularrisk AT olgamediano obstructivesleepapnoeasyndromecontinuouspositiveairwaypressuretherapyforpreventionofcardiovascularrisk |